News – Page 1094 – Endpoints News

Top scientists and BD execs craft Cullinan, a $150 million R&D portfolio shop focused on cancer

8 years ago

Top trend #4: We’re coming to a tipping point on cancer R&D, and it may not be pretty

8 years ago

Rigel surges as FDA waives panel; Troubled Endocyte looks for comeback following $12M licensing deal; Seattle ...

8 years ago

Sam Kulkarni takes the helm at CRISPR Therapeutics as founding CEO steps down

8 years ago

Biohaven skunked by a placebo in PhII/III flop for ataxia drug, shares slide

8 years ago

In the wake of a drubbing, Vivek Ramaswamy gambles $116M on Arbutus’ hep B work

8 years ago

With an FDA decision looming, Dynavax is shopping a deal on Heplisav — report

8 years ago

Ablynx spikes as PhIII aTTP study comes through with promising data, setting up an FDA application

8 years ago

Genzyme vet David Meeker takes helm at stealthy KSQ with $76M and a new map for drug discovery

8 years ago

Chris Carpenter joins the R&D exodus out of pharma; George Church's eGenesis selects Jodie Morrison as new CEO

8 years ago

Biotech makes a $303M run on Wall Street; Billionaire Thiel backs a startup round for antibiotic developer

8 years ago

The hep C pipeline shrivels as Merck dumps two next-gen combos, boosting leader Gilead

8 years ago

Zogenix rockets up as PhIII study offers impressive data on Dravet syndrome, vaulting over a rival

8 years ago

Eli Lilly R&D chief Jan Lundberg heads for the exit as CEO assembles a new team at the top

8 years ago

FDA commissioner Gottlieb's travel preferences? Commercial jets, a la mode

8 years ago

Prothena carefully explains why it's killing a psoriasis drug after PhIb

8 years ago

FDA experts turn thumbs down on PTC’s wobbly case for its Duchenne MD drug

8 years ago

The $913M bonanza: Arie Belldegrun and his top team at Kite show you how to make a really rich deal

8 years ago

Focused on PhIII, BeiGene touts early PD-1 results; Amgen partners with Simcere on China biosimilars work

8 years ago

AbbVie wins a 5-year free pass on mega-blockbuster Humira in biosim settlement with rival Amgen

8 years ago

Buyout buzz: Novartis has been kicking the tires at AAA as FDA reviews Lutathera — report

8 years ago

After getting crushed by bad data, Zynerba says its cannabis-based drug worked on Fragile X symptoms

8 years ago

Arcturus reverse merges into the market, steering RNA projects to the clinic

8 years ago

Open water: NIBR chief Jay Bradner partners with UC Berkeley on protein drug research institute

8 years ago

First page Previous page 1091 1092 109310941095 1096 1097 Next page Last page